MISSISSAUGA, Ontario--(BUSINESS WIRE)--
Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.
The detailed results of the votes by proxy and virtual votes received at the Meeting are as follows:
DIRECTOR NOMINEES
NUMBER OF SHARES
PERCENTAGE OF VOTES CAST
FOR
WITHHELD
FOR
WITHHELD
Daniel Chicoine
3,229,640
334,343
90.62
9.38
Anthony Dobranowski
3,293,159
270,824
92.40
7.60
Robert Harris
3,319,014
244,969
93.13
6.87
John London
3,112,855
451,128
87.34
12.66
Mary Ritchie
3,364,247
199,736
94.40
5.60
Dale MacCandlish Weil
3,363,540
200,443
94.38
5.62
In addition, the Company reports that the appointment of Ernst & Young LLP as the Company’s auditors for the ensuing fiscal year was passed by a majority of the votes represented at the Meeting. The Company’s full report of voting results on matters presented at the Meeting can be found at www.sedar.com.
About Miravo Healthcare
Miravo is a Canadian-focused, healthcare company with global reach and a diversified portfolio of commercial products. The Company targets several therapeutic areas, including pain, allergy, neurology and dermatology. The Company’s strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets. Miravo’s head office is located in Mississauga, Ontario, Canada, the international operations are located in Dublin, Ireland and the Company’s manufacturing facility is located in Varennes, Québec, Canada. The Varennes facility operates in a Good Manufacturing Practices (GMP) environment respecting the U.S., Canada and E.U. GMP regulations and is regularly inspected by Health Canada and the U.S. Food and Drug Administration. For additional information, please visit www.miravohealthcare.com.
